^
    Apply
    Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma (NCT04353375)
    Phase 2
    Hutchmed
    Recruiting
    Last update posted :
    07/06/2023
    Initiation :
    09/03/2020
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    FGFR2
    |
    FGFR2 fusion
    |
    fanregratinib (HMPL-453)
    HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors (NCT05173142)
    Phase 1/2
    Hutchison Medipharma Limited
    Recruiting
    Last update posted :
    03/08/2022
    Initiation :
    01/22/2022
    Primary completion :
    09/01/2024
    Completion :
    08/01/2025
    FGFR
    |
    PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation
    |
    cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)
    HMPL-453 in Advanced Malignant Mesothelioma (NCT04290325)
    Phase 2
    Hutchison Medipharma Limited
    Recruiting
    Last update posted :
    06/16/2020
    Initiation :
    12/30/2019
    Primary completion :
    11/30/2022
    Completion :
    03/17/2023
    FGFR
    |
    fanregratinib (HMPL-453)
    A Study of HMPL-453 in Patients With Advanced Solid Malignancies (NCT03160833)
    Phase 1/2
    Hutchison Medipharma Limited
    Unknown status
    Last update posted :
    02/13/2020
    Initiation :
    05/23/2017
    Primary completion :
    12/31/2019
    Completion :
    06/30/2020
    FGFR
    |
    fanregratinib (HMPL-453)